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Abstract
Background: It is controversial to what degree a+-thalassaemia protects against episodes of uncomplicated
malaria and febrile disease due to infections other than Plasmodium.
Methods: In Tanzania, in children aged 6-60 months and height-for-age z-score < -1.5 SD (n = 612), rates of fevers
due to malaria and other causes were compared between those with heterozygous or homozygotes a
+-thalassaemia and those with a normal genotype, using Cox regression models that accounted for multiple events
per child.
Results: The overall incidence of malaria was 3.0/child-year (1, 572/526 child-years); no differences were found in
malaria rates between genotypes (hazard ratios, 95% CI: 0.93, 0.82-1.06 and 0.91, 0.73-1.14 for heterozygotes and
homozygotes respectively, adjusted for baseline factors that were predictive for outcome). However, this
association strongly depended on age: among children aged 6-17 months, those with a+-thalassaemia experienced
episodes more frequently than those with a normal genotype (1.30, 1.02-1.65 and 1.15, 0.80-1.65 for heterozygotes
and homozygotes respectively), whereas among their peers aged 18-60 months, a+-thalassaemia protected against
malaria (0.80, 0.68-0.95 and 0.78, 0.60-1.03; p-value for interaction 0.001 and 0.10 for hetero- and homozygotes
respectively). No effect was observed on non-malarial febrile episodes.
Conclusions: In this population, the association between a+-thalassaemia and malaria depends on age. Our data
suggest that protection by a+-thalassaemia is conferred by more efficient acquisition of malaria-specific immunity.
Background
Alpha+-thalassaemia is a common genetic trait in
malaria-endemic areas in sub-Saharan Africa, Asia and
Melanesia, and may protect against the decline in hae-
moglobin concentration that is associated with asympto-
matic Plasmodium infection [1].
Case-control studies [2-4] and two cohort studies [5,6]
have consistently shown that a+-thalassaemia is asso-
ciated with reduced risks of severe malaria. Reports on
its effect on uncomplicated malaria are inconsistent. A
study in Vanuatu showed that, among children aged < 5
years, homozygous (but not heterozygous) a
+-thalassaemia was associated with an increased inci-
dence of uncomplicated malaria due to both Plasmo-
dium vivax and Plasmodium falciparum (incidence
ratio, 95% CI: 2.2, 1.3-2.7 and 1.6, 1.0-2.6, respectively);
paradoxically, among children aged 5-9 years, there was
no evidence of such an association [7]. Subsequent stu-
dies in Africa found no effect [6,8,9] or protection [10]
by a+-thalassaemia against uncomplicated malaria due
to P. falciparum.
In a prospective case-control study in Papua New Gui-
nean children, a+-thalassaemia was also strongly protec-
tive against hospitalization for disease episodes caused
by infections other than malaria [2].
In this study among preschool children, it was aimed
to assess effects of a+-thalassaemia on rates of fevers* Correspondence: hans.verhoef@wur.nl1Wageningen University, Cell Biology and Immunology Group, Wageningen,
The Netherlands
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due to malaria and fever due to other causes, and evalu-
ated to what extent these effects depended on age.
Methods
Study area and population
The study was conducted in February 2008-March 2009
in Handeni District, north-eastern Tanzania. The popu-
lation is a mixture of many different tribes, residing in
scattered hamlets, and mainly comprises poor farmer
families engaged in subsistence farming. Transmission
of malaria (> 95% due to P. falciparum) is intense and
perennial, with entomological inoculation rates of 35-
400 infectious bites per person-year [11]. Access to pri-
mary health care is limited. Artemether-lumefantrine
was the first-line treatment for uncomplicated malaria,
and available for free only in public care facilities, but
not in local shops; accordingly, home treatment with
efficacious anti-malarial drugs probably occurred only
sporadically.
Study design
This prospective cohort study was part of a double-blind
randomized trial aimed at measuring the effects of pre-
ventive supplementation with zinc and other multi-
nutrients on the incidence of malaria. Details about
study design will be reported elsewhere. During the fol-
low-up period, children received daily supplements
under supervision. Parents were encouraged to bring
their children to the research dispensary for fever or
other signs of illness.
Ethical approval
Ethical approval was provided by the review committees
in The Netherlands and Tanzania. Individual written
consent was obtained from parents.
Recruitment
Before recruitment (February-August 2008), a census
was conducted and all resident children aged < 60
months were registered. Parents and guardians were
invited to bring their children for screening. A medical
examination was performed by a clinical officer, anthro-
pometric indices were calculated as the average of two
recordings taken at consecutive days, and venous blood
samples were collected. An aliquot of blood was centri-
fuged immediately after collection, and a 90 μL red cell
pellet including the buffy coat was mixed with 90 μL
phosphate-buffered saline and 180 μL of a DNA stabiliz-
ing buffer (AS1; Qiagen, Hilden, Germany) and stored at
4°C for subsequent genotyping. Plasma was stored in
liquid nitrogen. A second aliquot of whole blood was
examined by haematology analyzer (Sysmex KX21,
Kobe, Japan) the same day.
Children were eligible for randomization when aged 6-
59 months, and with height-for-age z-score < -1.5 SD.
Children with weight-for-age z-score < -3 SD, haemo-
globin concentration < 70 g/L, signs of severe or chronic
disease, those unlikely to comply with interventions, or
whose parents/guardians refused consent were excluded.
Eligible children were randomly allocated to receive
daily supplements with zinc alone, zinc in combination
with other micronutrients, micronutrients alone, or pla-
cebo. Block randomization was used within six strata
defined by Plasmodium infection and age class (6-17
months, 18-35 months and 36-60 months). Children
with Plasmodium infection at baseline were treated with
artemether-lumefantrine (Novartis Pharma, Basel,
Switzerland).
Follow-up
A clinical officer was on 24-h duty at the research clinic.
For any child reporting with fever (axillary temperature
≥ 37.5°C) or a history of fever according to the guardian,
a finger-prick blood sample was collected to detect the
presence of malaria parasites. For all children with a
positive dipstick we measured whole blood concentra-
tions of haemoglobin and C-reactive protein. Children
were treated free of charge, and referred to the district
hospital when indicated.
Laboratory procedures
In samples collected at baseline and from sick children,
the presence of parasite-specific lactate dehydrogenase
(P. falciparum and other Plasmodium species) was
detected by rapid test (CareStart™, Access Bio, Mon-
mouth Jct, USA). This test has a sensitivity of 96% for
blood samples with > 50 parasites/μL as determined by
microscopy [12]. Blood films were prepared using stan-
dard methods. For slides of sick children, parasites were
counted against at least 200 leukocytes, and parasite
density was calculated assuming 8,000 leukocytes/μL. At
least 500 leukocytes were counted before a slide was
considered negative. When densities were very high,
parasites were counted per 2,000 erythrocytes, with esti-
mates of erythrocyte density based on the haemoglobin
concentration measured at the time of the episode,
using a linear model based on survey data to describe
the relationship between haemoglobin concentration
and erythrocyte count.
DNA was isolated from erythrocyte pellets (Qiagen
isolation kit); the -a3, 7 deletion type of a+-thalassaemia
was determined by polymerase chain reaction [13]. This
type of deletion is the most common form of a+-thalas-
saemia in Africa [14], with prevalence values often
exceeding 50% in eastern Africa [1,10,14]; other types of
thalassaemia are rare.
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Whole-blood concentrations of haemoglobin and C-
reactive protein were measured using point-of-care tests
(HemoCue, Ängelholm, Sweden and QuikRead, Orion
Diagnostica, Espoo, Finland, respectively). Plasma con-
centrations of C-reactive protein and ferritin for survey
samples were measured in The Netherlands (Meander
Medical Centre, Amersfoort) on a Beckman Coulter
Unicel DxC880i system according to the manufacturer’s
instructions. Plasma concentrations of P. falciparum-
specific histidine-rich protein-2 (HRP2) in samples col-
lected during the first malaria episode were measured
using a commercial enzyme-linked immunosorbent
assay kit (Malaria Ag Celisa; Cellabs, Brookvale NSW,
Australia). This protein is released into the plasma at
schizont rupture, and its plasma concentration may
more accurately represent total body parasite biomass,
because it also reflects the presence of sequestered para-
sites that remain undetected with conventional micro-
scopy [15].
Statistical analysis
Analyses were performed using SPSS (v15·0 for Win-
dows, SPSS, Chicago, IL), CIA (v2.1.2) [16] and STATA
(v11; College Station, Tx). Anthropometric indices were
calculated using Epi Info software (version 3.3.2) [17].
The primary outcome, an episode of malaria, was pre-
defined as a guardian-reported history of fever accompa-
nied by either an axillary temperature ≥ 37.5°C or
inflammation (whole blood C-reactive protein concen-
tration ≥ 8 g/L), plus a positive result for the pLDH
rapid dipstick test. Elevated C-reactive protein concen-
trations are probably indicative of recent malaria epi-
sodes in currently afebrile individuals with parasitaemia
[18,19], and are associated with the severity of malaria
(Veenemans and Verhoef, unpublished results). In the
primary analysis, a parasite density threshold was not
used to define malaria [20,21] because this can lead to
biased estimates of effects when the interventions act by
reducing (or increasing) parasite density [22,23], and
density estimates can vary greatly within short time
spans, ideally requiring leucocyte counts to be deter-
mined simultaneously [24,25]. To increase specificity of
malaria case definitions, Plasmodium-infected partici-
pants were treated at baseline to clear parasitaemia
before the start of surveillance. Episodes with parasitae-
mia thresholds of 5,000 and 10,000 parasites/μL were
considered as secondary outcomes. Children were pre-
sumed to be protected against new malaria infections
for 14 days after treatment with artemether-lumefan-
trine. Recurrent symptoms during this period were
assumed to be part of the initial episode and were not
counted as separate episodes. Additional outcomes were
hospital admissions or death due to infection-related
causes (combined end-point), non-malarial febrile
episodes (defined as any episode of reported fever that
did not classify as malaria, regardless of the presence or
absence of parasitaemia, and separated by at least two
days), and the severity of malaria episodes as indicated
by parasite density, haemoglobin concentrations, con-
centrations of whole blood C-reactive protein and
plasma HRP2.
In the primary analysis, group rates were compared
using Cox regression with robust estimates of the stan-
dard error to account for multiple episodes within chil-
dren. It was explored to what extent adjustment for
baseline factors that were prognostic for malaria (age
class, mosquito net use, Plasmodium infection, distance
between homestead and clinic, and height-for-age z-
score and micronutrient intervention) influenced the
estimates. Because it was anticipated that the effect of a
+-thalassemia would depend on age, a stratified analysis
was conducted within each of the three age classes used
for randomization, and interaction was assessed using a
Cox regression model. It was also explored whether
there was evidence of an interaction between a+-thalas-
saemia and the intervention by including interaction
terms in the Cox regression model. Incidence and inci-
dence ratios were calculated based on time to first epi-
sodes, and Cox regression models were used to obtain
adjusted hazard ratios.
Associations between a+-thalassaemia and continuous
variables (log-transformed as appropriate to obtain nor-
mal distributions) were assessed by ANOVA and multi-
ple linear regression.
Results
Of 1,029 children screened, 612 children were enrolled
(Figure 1). During follow-up, 20 of 612 (3%) children
were lost (three died; two were withdrawn by parents;
15 moved away).
Of 612 children included for follow-up, 304 (50%) had
a normal genotype, 41% (251) were heterozygous, 9%
(55) were homozygous; genotyping could not be per-
formed for 2 children. Plasmodium infection was
detected in 265 children (43%), virtually all due to P. fal-
ciparum (261), with similar prevalence values among
genotypes. Homozygotes had lower haemoglobin con-
centrations and height-for-age z-scores, seemed slightly
younger, appeared to have a higher prevalence of iron
deficiency, and used mosquito nets less frequently than
those with a normal genotype. They also less frequently
received zinc supplements, with or without multi-nutri-
ents (Table 1). Children with heterozygous and normal
genotype were similar in factors prognostic for malaria.
Haemoglobin concentrations were lower among children
with a+-thalassaemia.
Of 2,462 episodes of reported fever, 1,618 had a positive
dipstick test result; 1,572 malaria episodes were recorded
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in 526 child-years of observation. The incidence of malaria
was 3.0/child-year; 507 children (83%) experienced at least
one malaria episode, recurrent episodes occurred in 395
(63%) of children. The remaining 890 febrile episodes
were classified as not being due to malaria; of these, 27
(3%) were associated with a positive result for a malaria
dipstick test, but in these cases, fever could not be con-
firmed and plasma C-reactive protein concentration was <
8 mg/L. The incidence of non-malarial fever cases was
1.69/child-year. Hospital referral for infection-related
causes occurred in 68 cases, of which 30 were malaria (19
cases with haemoglobin concentration < 60 g/L, all except
one without signs of heart failure or respiratory distress).
Malaria incidence decreased with age class (3.73, 3.48 and
2.19 episodes/child-year for age classes 6-17, 18-35 and
36-59 months respectively; p < < 0.001); the corresponding
incidence estimates for episodes with haemoglobin con-
centration < 80 g/L were 0.82, 0.33 and 0.09 episodes/
child-year, respectively).
Rates of malaria were similar among genotypes (Table
2, Figure 2), whether analysed with or without adjust-
ment for mosquito net use, Plasmodium infection at
baseline, distance to the research clinic, stunting and
experimental intervention. Stratification by age-class,
however, showed that heterozygotes had increased
malaria rates when aged < 18 months (hazard ratio: 1.30,
1.02-1.65), whereas they were protected against malaria
when aged ≥ 18 months (Figure 2; hazard ratio: 0.80,
0.68-0.95; p-value for interaction: 0.001). A similar pat-
tern occurred in homozygotes, even though estimates
were less precise due to the smaller number of cases
(hazard ratio: 0.78, 0.60-1.03; p-value for interaction:
0.10). Restriction of the analysis to malaria cases with
parasite densities above 5,000/μL, 10,000/μL or 100,000/
μL resulted in similar overall estimates (Table 2), and
similar age-dependent patterns with and without adjust-
ment for baseline factors prognostic for malaria (data
shown for episodes with > 10,000 parasites/μL in Figure
3; p-values for interaction: 0.001 and 0.05, for heterozy-
gotes and homozygotes respectively). Similar effect esti-
mates were also obtained when taking account potential
interaction between the intervention and a+-thalassae-
mia, and there was no evidence that the magnitude of the
effects of a+-thalassaemia on malaria rates were influ-
enced by the intervention (p = 0.94 and 0.95 for interac-
tion with heterozygotes and homozygotes, respectively).
The rate of episodes with haemoglobin concentrations
< 80 g/L was highest among homozygotes and lowest
among children with a normal genotype, regardless of
age.
When genotype was not taken into account, parasite
densities during the first malaria episode declined with
age (p < < 0.001; Figure 4). In children aged below 18
months, a+-thalassaemia seemed associated with
increased parasite densities (Figure 3), although the sta-
tistical evidence for such an association was weak (p =
0.18). For homozygotes, the association between geno-
type and density seemed to depend on age (p = 0.04),
while for heterozygotes there was no such evidence (p =
0.78). a+-thalassaemia was not found to be associated
with parasite density in older age groups (Figure 4).
Other indicators of severity (plasma concentrations of
C-reactive protein or HRP2) were comparable between
genotypes, whether analyzed for all age classes com-
bined or separately (data not shown).
The declines in average haemoglobin concentrations
between baseline and the first malaria episode were only
minor and not substantially different in hetero- or
homozygotes (-4.5 g/L and -2.1 g/L) from values
observed in children with a normal genotype (-3.0 g/L).
Lastly, the rate of non-malaria febrile episodes was
similar between genotypes (Table 2); stratification by
age did not indicate differences in age-specific effects.
Discussion
In this cohort, a+-thalassaemia was associated with
increased rates of malaria in children aged < 18 months,
Figure 1 Study profile.
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but with protection against malaria in older children.
There was no evidence that a+-thalassaemia was asso-
ciated with the severity of malaria episodes as measured
by haemoglobin concentrations and other indicators.
Although all Plasmodium-infected children were treated
at baseline, the specificity of our case definition may have
gradually decreased with time, as more children became
asymptomatically infected. Similar results were obtained,
however, when restricting the analysis to cases with para-
site densities > 10,000/μL or > 100,000/μL. Because these
case definitions are more specific for detecting true
malaria cases, it is unlikely that a low specificity affected
the validity of the conclusions drawn in this report.
Because effect estimates were adjusted for factors
associated with malaria risk (including distance to the
research facility and intervention), it is unlikely that a
difference in external factors (such as intervention,
exposure to infection or health seeking behaviour)
biased the estimates and would be responsible for the
increased risk associated with a+-thalassaemia in the
youngest children. It remains unclear however, what
mechanism could underlie the increased incidence in
the youngest children. It has been put forward that Plas-
modium parasites preferentially invade reticulocytes
[26,27]. Thus reticulocytosis, induced by thalassaemia-
associated ineffective erythropoiesis, would favour prolif-
eration of Plasmodium parasites [28]. However, there
was no strong support that thalassaemia was associated
with increased parasite densities in young children, and
neither did any previous study. In addition, a recent
study found no evidence that reticulocyte counts were
increased in individuals with a+-thalassaemia [29].
Table 1 Baseline characteristics of study participants and distribution of malaria prognostic factors, by genotype
Normal
(aa/aa)
Heterozygote
(-a/aa)
p Homozygote
(-a/-a)
p
n 304 (50%) 251 (41%) 55 (9%)
Sex, M/F [n/n] 50%/50%
[151/153]
46%/54%
[116/135]
0.44 54%/46%
[30/25]
0.56
Age, months 33.4 ± 15.9 32.0 ± 15.2 0.27 29.9 ± 16.0 0.12
Age class 0.65 0.08
6-17 months 21% 64 24% [61] 35% [19]
18-35 months 36% [108] 35% [87] 33% [18]
36-59 months 41% [132] 41% [103] 42% [18]
Plasmodium infection * 44% [134] 43% [107] 0.80 42% [23] 0.77
Anaemia ¶ 62% [189] 71% [178] 0.03 87% [48] < 0.001
Haemoglobin concentrations, g/L 104.7 ± 12.5 102.2 ± 12.4 0.02 94.9 ± 12.8 < 0.001
Without Plasmodium infection 106.7 ± 12.6 104.8 ± 11.6 0.14 95.3 ± 13.9 < 0.001
With Plasmodium infection 102.0 ± 11.8 98.8 ± 12.5 0.04 94.3 ± 11.3 0.005
Inflammation † 32% [99] 33% [82] 0.99 38% [21] 0.62
Mosquito net use †† 34% [101] 33% [82] 0.92 18% [10] 0.03
Height-for-age z-score -2.38 ± 0.72 -2.43 ± 0.64 0.28 -2.63 ± 0.75 0.01
Distance from homestead to dispensary, km ** 3.56 ± 2.21 3.65 ± 2.28 0.62 3.36 ± 1.84 0.54
Intervention
Placebo 26% [78] 22% [54] 38% [21]
Zinc 25% [76] 27% [67] 18% [10]
Multi-nutrients without zinc 23% [71] 27% [68] 27% [15]
Multi-nutrients with zinc 26% [79] 25% [62] 16% [9]
Iron deficiency ∥
All children 15% [46] 20% [49] 0.17 26% [14] 0.08
Without inflammation [n/n] § 22% [45/205] 25% [41/167] 0.80 35% [12/34] 0.13
Mean ± SD, % [n] or median (25- and 75-percentiles) unless indicated otherwise. P-values for differences relative to the reference group of children with normal
genotype were obtained by Pearson Chi-Square test (age class), Fischer’s Exact test (anaemia, Plasmodium infection, inflammation, mosquito net use, iron
deficiency), or Students t-test (continuous variables). Because interventions were randomly allocated, no p-values are provided for intervention groups.
¶ Haemoglobin concentration < 110 g/L
* As indicated by a positive result for pLDH-based dipstick test (see text).
† Plasma C-reactive protein concentration ≥ 8 mg/L
†† Data missing for 11 children.
** Measured as the crow flies, based on global positioning data.
∥ Plasma ferritin concentration < 12 μg/L (6 missing values).
§ Restricted to children plasma C-reactive protein concentration ≥ 8 mg/L
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Others hypothesized that increased parasite-induced
surface expression of neo-antigens on thalassaemic ery-
throcytes results in enhanced binding of IgG antibody
and more rapid clearance of parasitized erythrocytes in
the spleen [30]. Clearance in the spleen may be further
enhanced by a reduced erythrocyte deformability of
thalassaemic cells [31]. In children aged 6-18 months,
in whom protection by maternal antibodies has waned,
but acquired immunity is still low and parasite replica-
tion only partly restrained by an effective circulating
antibody repertoire, such increased antigen presenta-
tion in the spleen may result in a more rapid develop-
ment of symptoms, and at the same time a more
efficient and more rapid acquisition of protective
immunity. Further evidence to support this theory is,
however, lacking.
Nevertheless, the findings reported here contribute to
existing epidemiological evidence that predisposition to
malaria due to P. falciparum in both heterozygotes and
homozygotes for a+-thalassaemia early in life may result
in protection against severe malaria, and (at older age)
uncomplicated malaria due to the same species. In
Vanuatu, the incidence of malaria due to P. falciparum
and P. vivax was increased in children aged < 5 years
with homozygous a+-thalassaemia relative to children
with normal genotype [7], but the study found no evi-
dence of protection among either hetero- or homozy-
gotes in children aged 5-9 years. Contrary to our
findings, the incidence in heterozygotes and children
with normal genotype were similar, regardless of
whether the analysis was stratified by age or not. The
estimates in the current report are more precise, how-
ever, due to the larger number of malaria cases in this
study (622 and 812 in children with heterozygote and
normal genotypes, respectively, versus 159 and 304 in
Vanuatu). In an area adjacent that used in the current
report, with similar levels of malaria endemicity, a+-tha-
lassaemia was found to be associated with protection
against malaria in children aged 6 months to 20 years
[10]. This protection seemed more pronounced among
children aged > 5 years, but the analysis was based on
50 episodes (41 among children aged < 5 years) and had
insufficient precision to adequately assess age-specific
effects in early life.
Table 2 Rates of uncomplicated malaria, non-malarial febrile episodes and severe events (hospital admission or death),
by genotype
Event Normal
(aa/aa)
Heterozygotes
(-a/aa)
Homozygotes
(-a/-a)
All episodes of malaria
Incidence (n/child-years) 3.10 (812/262) 2.89 (622/215) 2.83 (136/48)
Hazard ratio, crude 1.00 Reference 0.93 [0.80-1.06] 0.92 [0.73-1.14]
Hazard ratio, adjusted † 1.00 Reference 0.93 [0.82-1.06] 0.91 [0.73-1.14]
Episodes with parasitaemia > 5,000/μL (1,249) 1.00 Reference 0.94 [0.81-1.10] 0.89 [0.67-1.17]
Episodes with parasitaemia > 10,000/μL (1,119) 1.00 Reference 0.95 [0.81-1.11] 0.91 [0.68-1.22]
Episodes with parasitaemia > 100,000/μL (263) 1.00 Reference 0.94 [0.69-1.29] 0.98 [0.57-1.69]
Episodes with haemoglobin concentration < 80 g/L (178) 1.00 Reference 1.25 [0.86-1.84] 2.65 [1.71-4.10]
1st episodes of malaria
Incidence (n/child-years) 3.08 (257/84) 2.66 (199/75) 3.44 (49/14)
Incidence rate ratio 1.00 Reference 0.86 [0.71-1.04] 1.12 [0.81-1.52]
Hazard ratio, crude 1.00 Reference 0.90 [0.75-1.09] 1.10 [0.81-1.49]
Hazard ratio, adjusted † 1.00 Reference 0.89 [0.74-1.08] 1.06 [[0.78-1.44]
All episodes of non-malarial fever
Incidence (n/child-years) 1.64 (431/262) 1.72 (370/215) 1.82 (87/48)
Hazard ratio, crude 1.00 Reference 1.04 [0.85-1.28] 1.10 [0.82-1.49]
Hazard ratio, adjusted ¶ 1.00 Reference 1.00 [0.84-1.19] 0.98 [0.73-1.36]
All hospital admissions or deaths §
Incidence (n/child-years) 0.15 (39/262) 0.10 (21/215) 0.19 (9/48)
Hazard ratio, crude 1.00 Reference 0.66 [0.38-1.14] 1.26 [0.56-2.89]
Hazard ratio, adjusted ¶ 1.00 Reference 0.57 [0.33-0.98] 0.89 [0.36-2.24]
Values between brackets indicate (cases), (cases/child-year) or [95% CIs].
† Adjusted for experimental intervention (indicated by dummies), mosquito net use, distance between homestead and research clinic, height-for-age z-score and
Plasmodium infection at baseline. There was no evidence of an interaction between genotype and experimental intervention.
¶ Adjusted for age class, experimental intervention (dummies), distance between homestead and research clinic, height-for-age z-score and Plasmodium infection
at baseline.
§ Hospital admissions or deaths (of which two occurred outside hospital) for infection-related causes, excluding events due to trauma, poisoning or burns (one
case occurred in a child for whom the genotype could not be determined).
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Because the intensity of malaria exposure determines
how fast protective immunity is obtained, the age at
which a difference in protective immunity between chil-
dren with and without a+-thalassaemia becomes evident
shall vary with transmission intensity. This may at least
in part explain differences between studies; under condi-
tions of intense transmission, such as in the present
study, the difference attained would become evident ear-
lier in life than in conditions of less intense transmission
such as encountered in Vanuatu [7].
The finding that a+-thalassaemia is associated with an
increased frequency of malaria in children aged 6-18
months may seem to contradict reports from hospital-
based studies that a+-thalassaemia protects against
severe malarial anaemia [4,6], which has the highest
incidence in the same age range [32]. An increased fever
rate may, however, not necessarily translate to an
increased risk of severe malaria anaemia if the decline in
haemoglobin during these attacks is halted or suffi-
ciently slowed down to before reaching a critical level
that leads to admission. A potential mechanism for such
phenomenon has recently been proposed [33]. In thalas-
saemia, the total amount of haemoglobin is divided over
erythrocytes that are disproportionately increased in
numbers but reduced in size and haemoglobin content.
Thus, an equal proportion of erythrocytes being
destroyed by malaria parasites results in a smaller hae-
moglobin reduction in individuals with a+-thalassaemia
than in their peers with normal genotype.
When analysing the decline in haemoglobin concen-
tration between baseline and first malaria episode, we
did not find evidence of such protection. It should be
Figure 2 Association between a+-thalassaemia and malaria rates, overall and by age class. Episodes as predefined (see text). Line bars
and values between brackets indicate 95% CIs. Estimates adjusted for baseline Plasmodium infection status, distance between homestead and
clinic (continuous variable), height-for-age z-score (continuous variable), mosquito net use and experimental intervention.; corresponding p-
values for the difference in hazard ratios between children < 18 months and ≥ 18 months: 0.006 and 0.18, for hetero-and homozygotes
respectively.
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Figure 3 Association between a+-thalassaemia and malaria rates, overall and by age class (episodes with densities > 10,000/μL).
Malaria episodes as predefined, but with densities of asexual parasites > 10,000/μL. Estimates were adjusted as described in Figure 2; p-values
for the difference in hazard ratios between children < 18 months and ≥ 18 months: 0.002 and 0.07, for hetero-and homozygotes respectively.
Figure 4 Association between a+-thalassaemia and parasite density during first episode of malaria, by age class. Markers and line bars
indicate geometric means and 95% CIs, respectively; p-values for differences between genotypes within age classes obtained by ANOVA).
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noted, however, that the average decline in haemoglobin
concentration during malaria episodes was relatively
small, and that very few (19) episodes occurred whereby
haemoglobin concentrations dropped below 60 g/L. This
is probably due to good access to treatment in our
study, and haematological gains due to the nutrient
interventions. By contrast, in a pilot survey in the same
area in 2006, children with a+-thalassaemia were found
to be protected against the decline in haemoglobin con-
centration associated with mild and asymptomatic infec-
tions [1]. At that time, there were no first-line health
facilities in the area, and artemether-lumefantrine was
not available through public facilities. Thus this setting
was probably better comparable to the circumstances
under which a+-thalassaemia has been providing a sur-
vival advantage in the past.
A likely explanation for the increased rates of episodes
with haemoglobin concentrations < 80 g/L observed in
heterozygotes and homozygotes (Table 2) is that chil-
dren with these genotypes had lower initial haemoglobin
concentrations before the onset of malaria episodes than
children with normal genotype. Thus a reduction in
haemoglobin concentration caused by malaria in hetero-
zygotes and homozygotes will more readily result in
haemoglobin concentrations dropping below a threshold
of 80 g/L.
Conclusions
In pre-school Tanzanian children living in an area of
intense transmission, and with height-for-age z-score <
-1.5 SD, effects of a+-thalassaemia on malaria rates were
age-dependent: it was associated with increased rates in
children aged < 18 months as opposed to decreased
rates in older children. There was no evidence that a
+-thalassaemia was associated with the severity of
malaria episodes.
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